Tags

Type your tag names separated by a space and hit enter

Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection.
Clin Vaccine Immunol. 2007 Nov; 14(11):1433-6.CV

Abstract

An indirect immunofluorescent assay (Euroimmun AG, Luebeck, Germany) was used to investigate the avidity of immunoglobulin G (IgG), IgM, IgA, and total Ig (IgGAM) antibody responses to severe acute respiratory syndrome coronavirus (SARS CoV) infections. Serial serum samples from eight patients collected during the first, third, and ninth months after the onset of infection were evaluated. It was found that low-avidity IgG antibodies were detected in 15/15 (100%), 1/5 (20%), and 0/8 (0%) serum samples collected during the first, third, and ninth months after the onset of symptoms, respectively. Low-avidity antibodies of IgA and IgM subclasses were detected in 14/14 (100%) and 3/14 (21%) serum samples, respectively, collected in the first month after the onset of infection. However, IgA antibodies remained low in avidity in a proportion of patients even during late convalescence. As a consequence, IgG antibody avidity assays gave better discrimination between acute-phase and late-convalescent-phase serum samples than IgM, IgA, or IgGAM assays. In two of these patients, sequential serum samples were also tested for IgG avidity against human CoV strains OC43 and 229E in parallel. While SARS CoV infections induced an anamnestic IgG antibody response to the 229E and OC43 viruses, these cross-reactive antibodies remained of high avidity from early (the first month) postinfection. The results showed that assays to detect low-avidity antibody may be useful for discriminating early from late antibody responses and also for distinguishing anamnestic cross-reactive antibody responses from primary specific responses. This may be useful in some clinical situations.

Links

PMC Free PDF
PMC Free Full Text
FREE Publisher Full Text

Authors+Show Affiliations

Chan KH
Department of Microbiology, University Pathology Building, Queen Mary Hospital Compound, Pokfulam, Hong Kong, SAR, People's Republic of China.
Sonnenberg K
No affiliation info available
Niedrig M
No affiliation info available
Lam SY
No affiliation info available
Pang CM
No affiliation info available
Chan KM
No affiliation info available
Ma SK
No affiliation info available
Seto WH
No affiliation info available
Peiris JS
No affiliation info available

MeSH

Antibodies, ViralAntibody AffinityAntibody SpecificityCoronavirus 229E, HumanCoronavirus OC43, HumanFluorescent Antibody Technique, IndirectHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MSARS VirusSevere Acute Respiratory Syndrome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17881505

Citation

Chan, K H., et al. "Use of Antibody Avidity Assays for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection." Clinical and Vaccine Immunology : CVI, vol. 14, no. 11, 2007, pp. 1433-6.
Chan KH, Sonnenberg K, Niedrig M, et al. Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection. Clin Vaccine Immunol. 2007;14(11):1433-6.
Chan, K. H., Sonnenberg, K., Niedrig, M., Lam, S. Y., Pang, C. M., Chan, K. M., Ma, S. K., Seto, W. H., & Peiris, J. S. (2007). Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection. Clinical and Vaccine Immunology : CVI, 14(11), 1433-6.
Chan KH, et al. Use of Antibody Avidity Assays for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection. Clin Vaccine Immunol. 2007;14(11):1433-6. PubMed PMID: 17881505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection. AU - Chan,K H, AU - Sonnenberg,K, AU - Niedrig,M, AU - Lam,S Y, AU - Pang,C M, AU - Chan,K M, AU - Ma,S K, AU - Seto,W H, AU - Peiris,J S M, Y1 - 2007/09/19/ PY - 2007/9/21/pubmed PY - 2008/1/15/medline PY - 2007/9/21/entrez SP - 1433 EP - 6 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 14 IS - 11 N2 - An indirect immunofluorescent assay (Euroimmun AG, Luebeck, Germany) was used to investigate the avidity of immunoglobulin G (IgG), IgM, IgA, and total Ig (IgGAM) antibody responses to severe acute respiratory syndrome coronavirus (SARS CoV) infections. Serial serum samples from eight patients collected during the first, third, and ninth months after the onset of infection were evaluated. It was found that low-avidity IgG antibodies were detected in 15/15 (100%), 1/5 (20%), and 0/8 (0%) serum samples collected during the first, third, and ninth months after the onset of symptoms, respectively. Low-avidity antibodies of IgA and IgM subclasses were detected in 14/14 (100%) and 3/14 (21%) serum samples, respectively, collected in the first month after the onset of infection. However, IgA antibodies remained low in avidity in a proportion of patients even during late convalescence. As a consequence, IgG antibody avidity assays gave better discrimination between acute-phase and late-convalescent-phase serum samples than IgM, IgA, or IgGAM assays. In two of these patients, sequential serum samples were also tested for IgG avidity against human CoV strains OC43 and 229E in parallel. While SARS CoV infections induced an anamnestic IgG antibody response to the 229E and OC43 viruses, these cross-reactive antibodies remained of high avidity from early (the first month) postinfection. The results showed that assays to detect low-avidity antibody may be useful for discriminating early from late antibody responses and also for distinguishing anamnestic cross-reactive antibody responses from primary specific responses. This may be useful in some clinical situations. SN - 1556-6811 UR - https://www.unboundmedicine.com/medline/citation/17881505/Use_of_antibody_avidity_assays_for_diagnosis_of_severe_acute_respiratory_syndrome_coronavirus_infection_ L2 - http://cvi.asm.org/cgi/pmidlookup?view=long&pmid=17881505 DB - PRIME DP - Unbound Medicine ER -